Browsing: Shock

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reaction underscored how sensitive investors are to clinical data, pipeline clarity, and competitive pressure from Eli Lilly’s obesity drugs. For you, this creates a chance to reassess exposure to companies tied…